Comparing Gilenya vs Ocrevus
| Gilenya (fingolimod) | Ocrevus (ocrelizumab) |
|
|---|
| Gilenya (fingolimod) | Ocrevus (ocrelizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Gilenya is an immunosuppressant that may be used to treat relapsing forms of MS in adults and children over the age of 10. It can increase your risk of infection and interact with multiple drugs, and... View more |
Prescription only
Ocrevus is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate, reducing inflammation in people with MS. After an initial loading dose, it is given by IV infusion every... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Gilenya (fingolimod) | More about Ocrevus (ocrelizumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Gilenya has an average rating of 7.1 out of 10 from a total of 95 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 18% reported a negative effect. |
Ocrevus has an average rating of 5.3 out of 10 from a total of 176 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 42% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Gilenya side effects |
View all Ocrevus side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Gilenya prices |
View all Ocrevus prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other fingolimod brands include: Tascenso ODT |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
216 hours |
624 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 642 drugs are known to interact with Gilenya:
|
A total of 433 drugs are known to interact with Ocrevus:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
September 21, 2010 |
March 28, 2017 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.